Century Therapeutics
IPSC
52 hedge funds and large institutions have $279M invested in Century Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 6 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 50 → 52 (+2)
1.02% less ownership
Funds ownership: 38.69% → 37.66% (-1%)
17% less capital invested
Capital invested by funds: $335M → $279M (-$56.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.6M |
| 3 |
BlackRock
New York
|
+$2.66M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.08M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$750K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.87M |
| 2 |
JP Morgan Chase
New York
|
-$1.08M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$846K |
| 4 |
Morgan Stanley
New York
|
-$834K |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$588K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFGIA
51
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| $1K | – | – | – |
|
|
O
52
OrbiMed
New York
| – | -$4.87M | -307,047 | Closed |
|
|
PM
53
Parametrica Management
Wanchai,
Hong Kong
| – | -$459K | -28,855 | Closed |
|
|
RA
54
Royce & Associates
New York
| – | -$205K | -12,900 | Closed |
|
|
SSA
55
Schonfeld Strategic Advisors
New York
| – | -$195K | -12,300 | Closed |
|
56
ProShare Advisors
Bethesda,
Maryland
| – | -$163K | -10,273 | Closed |
|
57
UBS Group
Zurich,
Switzerland
| – | -$72.8K | -5,496 | -99% |
|
58
Osaic Holdings
Scottsdale,
Arizona
| – | -$3K | -200 | Closed |
|
IPSC Hedge Fund Activity: Q1 2022 in Review
52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q1 2022, worth a combined $279M — down 17% from $335M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IPSC positions and 6 closed out — a net gain of 2 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $8.96M. The largest seller was OrbiMed, exiting entirely with an estimated $4.87M sold.
- 52 institutional investors held Century Therapeutics (IPSC) as of Q1 2022, up from 50 in Q4 2021.
- Funds reported $279M of Century Therapeutics stock for Q1 2022, down 17% quarter-over-quarter.
- 8 funds opened new Century Therapeutics positions in Q1 2022 and 6 closed out, a net change of +2 holders.
- The largest Century Therapeutics buyer in Q1 2022 was Deep Track Capital, an estimated $8.96M added.
- The largest Century Therapeutics seller in Q1 2022 was OrbiMed, an estimated $4.87M sold.
Based on aggregated 13F filings for Q1 2022.